GlassScriptPhysician profile
Sajjad Hussain
NPI 1780672188
$3,792.61
in general payments reported to CMS, 2019-2025
25 companies · $272 in 2025
The $272 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,237 · 2020: $760 · 2021: $660 · 2022: $449 · 2023: $294 · 2024: $120 · 2025: $272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $686.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $686.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,410.05 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $538.51 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $373.57 | 2019-2021 | |
| Medtronic, INC. | $273.73 | 2022-2025 | Minimed 780g |
| Janssen Pharmaceuticals, INC | $208.35 | 2019 | |
| Dexcom, INC. | $193.29 | 2021-2023 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $139.71 | 2019-2022 | |
| Inari Medical, INC. | $131.43 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $103.22 | 2022 | |
| Abbott Laboratories | $71.91 | 2019-2020 | |
| Corcept Therapeutics | $64.87 | 2020-2021 | |
| Amarin Pharma, INC. | $58.53 | 2019-2020 | |
| Becton, Dickinson and Company | $31.92 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $27.83 | 2019 | |
| Boston Scientific Corporation | $19.12 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lifescan, INC. | $16.97 | 2022 | |
| Daiichi Sankyo INC. | $16.14 | 2021 | |
| Mallinckrodt Hospital Products INC. | $15.23 | 2021 | |
| Harmony Biosciences LLC | $15.12 | 2021 | |
| Alnylam Pharmaceuticals INC. | $14.96 | 2019 | |
| Amryt Pharma Holdings LTD | $14.79 | 2022 | |
| Eisai INC. | $14.37 | 2021 | |
| Mallinckrodt Enterprises LLC | $13.71 | 2019 | |
| Circassia INC. | $13.64 | 2019 | |
| W. L. Gore & Associates, INC. | $11.64 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sajjad Hussain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.